Silexion begins GMP manufacturing of SIL204 with Catalent; Phase 2/3 trial approved at Israeli site

Silexion Therapeutics Corp

• Initiated GMP clinical batch manufacturing of SIL204 with Catalent at its Limoges, France center of excellence.
• Tel Aviv Sourasky Medical Center Helsinki Ethics Committee approved planned Phase 2/3 trial of SIL204 in LAPC.
• SIL204 is a next-generation siRNA therapy targeting mutated KRAS, most common oncogenic driver in cancers.
• Phase 2/3 trial to evaluate SIL204 with standard-of-care chemo using dual-route (intratumoral + systemic) administration.
• Israeli Ministry of Health already approved the trial; CTA submitted to Germany; preparing for first patient dosing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.